The estimated Net Worth of William Ludlam is at least $775 Thousand dollars as of 27 September 2019. William Ludlam owns over 5,050 units of Chiasma Inc stock worth over $44,364 and over the last 6 years he sold CHMA stock worth over $0. In addition, he makes $730,925 as Senior Vice President - Clinical Development and Medical Affairs at Chiasma Inc.
William has made over 2 trades of the Chiasma Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 5,050 units of CHMA stock worth $24,796 on 27 September 2019.
The largest trade he's ever made was buying 5,050 units of Chiasma Inc stock on 27 September 2019 worth over $24,796. On average, William trades about 1,113 units every 30 days since 2019. As of 27 September 2019 he still owns at least 11,799 units of Chiasma Inc stock.
You can see the complete history of William Ludlam stock trades at the bottom of the page.
Dr. William Ludlam, M.D., Ph. D. is Senior Vice President, Clinical Development and Medical Affairs of the Company since January 2017, and has served the Company in roles of increasing responsibility since August 2015. Prior to joining us, he served in various roles culminating in the position of Senior Medical Director of Novartis AG (NYSE: NVS), a multinational pharmaceutical company, from March 2012 to August 2015. Dr. Ludlam also founded and served as Medical Director of the Seattle Pituitary Center at the Swedish Medical Center and the Pituitary Unit at the Oregon Health & Sciences University in Portland, Oregon. Dr. Ludlam received his M.D. and Ph.D. (Developmental Neuroscience) from the Albert Einstein College of Medicine of Yeshiva University in 1995, and a B.S. in Chemistry from Whittier College in 1986.
As the Senior Vice President - Clinical Development and Medical Affairs of Chiasma Inc, the total compensation of William Ludlam at Chiasma Inc is $730,925. There are 3 executives at Chiasma Inc getting paid more, with Raj Kannan having the highest compensation of $6,413,280.
William Ludlam is 55, he's been the Senior Vice President - Clinical Development and Medical Affairs of Chiasma Inc since 2017. There are 6 older and 6 younger executives at Chiasma Inc. The oldest executive at Chiasma Inc is John Scarlett, 69, who is the Independent Director.
William's mailing address filed with the SEC is C/O CHIASMA, INC., 140 KENDRICK STREET BUILDING C EAST, NEEDHAM, MA, 02494.
Over the last 9 years, insiders at Chiasma Inc have traded over $0 worth of Chiasma Inc stock and bought 324,855 units worth $2,372,906 . The most active insiders traders include Llp Abingworth, Ansbert Gadicke, and John F Thero. On average, Chiasma Inc executives and independent directors trade stock every 85 days with the average trade being worth of $94,895. The most recent stock trade was executed by Roni Mamluk on 9 February 2021, trading 27,981 units of CHMA stock currently worth $51,765.
Chiasma is a commercial-stage biopharmaceutical company focused on developing and commercializing oral therapies to improve the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. In June 2020, Chiasma received FDA approval of MYCAPSSA for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA, the first and only oral somatostatin analog approved by the FDA, is available for commercial sale. Chiasma is headquartered in Needham, MA with a wholly owned subsidiary in Israel. MYCAPSSA, TPE and CHIASMA are registered trademarks of Chiasma.
Chiasma Inc executives and other stock owners filed with the SEC include: